| Description | Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is a mouse γ-type anti-recombinant antibody. It can specifically induce an antibody response against Neu-glycolyl GM3 ganglioside (NeuGcGM3), which is overexpressed in a variety of solid tumors. Racotumomab reacts with gangliosides containing NU-Glycolyl (NeuGc), thioglycosides, and other antigens expressed in tumors. Racotumomab has anti-cancer activity and can be used in the study of lung cancer. |
| In vitro | 通过诱导针对肿瘤细胞中存在的NeuGcGM3神经节苷脂的特异性体液和细胞免疫应答，racotumomab刺激细胞死亡[4]。 |
| In vivo | 在F3II细胞(s.c.)乳腺癌小鼠模型中，racotumomab（50 μg/剂量，i.p.）联合Keyhole limpet hemocyanin (KLH)能够抑制肿瘤生长[2]。针对3LL细胞(s.c.)小鼠皮下移植模型中的肺结节，racotumomab（50 μg/剂量，s.c.）与Pemetrexed（100 mg/kg）联用表现出高效的抑制效果[3]。然而，在3LL细胞(s.c.)小鼠皮下移植模型中，racotumomab（50-200 μg/剂量，s.c.）未展现出显著的抗肿瘤效果[3]。 |
| molecular weight | N/A |
| CAS | 946832-34-4 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Vázquez AM, et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2012 Oct 23;2:150. 2. Gajdosik Z. Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today (Barc). 2014 Apr;50(4):301-7. 3. Segatori VI, et al. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. Front Oncol. 2012 Nov 8;2:160. |